Skip to main content
Fig. 1 | Renal Replacement Therapy

Fig. 1

From: Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)

Fig. 1

Randomized controlled trials (RCTs) with erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease (CKD). For each published trial, the figure shows sample size, effectively achieved mean hemoglobin (Hb) levels in lower and higher anemia correction arms, and lower versus higher Hb targets, respectively. References of articles quoted in the figure: Suzuki M et al., 1989 [40]; Abraham PA et al., 1990 [41]; Watson AJ et al., 1990 [42]; CanEPO (Silberberg J et al), 1990 [43]; Bahlman JL et al., 1991 [44]; Clyne N et al., 1992 [45]; Morris KP et al., 1993 [46]; Sikole A et al., 1993 [47]; Roth D et al., 1994 [48]; Nissenson AR et al., 1995 [49]; Kuriyama S et al., 1997 [50]; Besarab A et al., 1999 [23]; McMahon LP et al., 1999 [51]; Foley RN et al., 2000 [52]; Furuland H et al., 2003 [53]; Gouva C et al., 2004 [54]; Roger SD et al., 2004 [55]; Parfrey PS et al., 2005 [56]; Levin A et al., 2005 [57]; Rossert J et al., 2006 [58]; Drueke T et al., 2006 [24]; Singh AK et al., 2006 [25]; Ritz E et al., 2007 [59]; TREAT (Pfeffer MA et al), 2009 [26]. Adapted and updated from NKF KDOQI™ [60]

Back to article page